中国戊型病毒性肝炎院内筛查管理流程专家共识(2023年版)

中国戊型肝炎研究协助组(CCSHE); 中国医师协会感染科医师分会; 国家感染性疾病临床医学研究中心

doi:10.3969/j.issn.1001-5256.2023.04.008

中国戊型病毒性肝炎院内筛查管理流程专家共识(2023年版)

DOI: 10.3969/j.issn.1001-5256.2023.04.008

利益冲突声明：所有作者均声明不存在利益冲突。

计量
- 文章访问数: 668
- HTML全文浏览量: 99
- PDF下载量: 291
- 被引次数: 0
出版历程
- 收稿日期: 2023-03-10
- 录用日期: 2023-03-30
- 出版日期: 2023-04-20

Expert consensus on the process of in-hospital screening and management of viral hepatitis E in China (2023)

摘要

摘要: 戊型病毒性肝炎(简称戊型肝炎)是由戊型肝炎病毒(HEV)引起的一种急慢性传染病。全球每年约发生2 000万例HEV感染，其中约有330万例戊型肝炎，7万例与HEV感染相关的死亡病例。过去10年我们对戊型肝炎的认识发生了巨大变化，我国仍有大部分HEV感染者，尤其是重症及慢性戊型肝炎患者被漏诊或误诊。根据世界卫生组织提出的到2030年消除病毒性肝炎这一公共卫生危害的目标，并基于医疗机构是目前我国诊断和治疗HEV的主要场所这一事实，中国戊型肝炎研究协助组(CCSHE)、中国医师协会感染科医师分会和国家感染性疾病临床医学研究中心共同制订了共识，希望促进医疗机构管理、疾病预防控制、临床、检验、感染控制的多学科、多部门联合，有效筛查和诊断HEV感染人群；帮助戊型肝炎患者及时会诊和转诊，优化患者随访及复诊管理流程，提供正确的治疗方法。同时加强非感染、非肝病专科医师对戊型肝炎的认知，以便在日常医疗活动中及时发现HEV感染者。
- 戊型肝炎 /
- 普查 /
- 诊断 /
- 治疗学 /
- 专家共识
Abstract: Hepatitis E caused by hepatitis E virus (HEV) infection is an acute /chronic infectious disease with significant morbidity and mortality, which has become an important global health issue. Our understanding of HEV has changed completely over the past decade. Every year 20 million people are infected with HEV, among whom hepatitis E occur in 3.3 million cases and 70 thousands die from HEV infection-related diseases globally. However, a majority of HEV infections, especially fulminant or chronic hepatitis E, are missed diagnosed or misdiagnosed in China. According the goal of eliminating viral hepatitis as a public health threat by 2030 set by the World Health Organization and based on the fact that medical institutions are the main facilities for diagnosis and treatment of Hepatitis E in China, we developed the Expert Consensus on the process of in-hospital screening and management of viral hepatitis E in China. The consensus intends to promote multi-disciplinary and multi-departmental collaboration in health care institutions, including hospital administration, infection control division, clinical departments and laboratory, to strengthen the screen, diagnosis, consultation, referral and treatment of patients with hepatitis E. Meanwhile, the consensus also intends to raise the awareness of hepatitis E among non-infectious and non-hepatic specialists, which would be conducive to timely detection and early diagnosis of hepatitis E.
- Hepatitis E /
- Mass Screening /
- Diagnosis /
- Therapeutics /
- Expert Consensus

HTML全文

图 1 戊型病毒性肝炎院内筛查、会诊、治疗和转诊流程

Figure 1. The process of in-hospital screening, consultation, treatment, and referral of viral hepatitis E

下载: 全尺寸图片幻灯片

参考文献(60)

[1]	KAMAR N, IZOPET J, PAVIO N, et al. Hepatitis E virus infection[J]. Nat Rev Dis Primers, 2017, 3: 17086. DOI: 10.1038/nrdp.2017.86.
[2]	XIANG Z, JIANG B, LI W, et al. The diagnostic and prognostic value of serum exosome-derived carbamoyl phosphate synthase 1 in HEV-related acute liver failure patients[J]. J Med Virol, 2022, 94(10): 5015-5025. DOI: 10.1002/jmv.27961.
[3]	TAKAHASHI K, TERADA S, KOKURYU H, et al. A wild boar-derived hepatitis E virus isolate presumably representing so far unidentified "genotype 5"[J]. Kanzo, 2010, 51(9): 536-538. DOI: 10.2957/kanzo.51.536.
[4]	TAKAHASHI M, NISHIZAWA T, SATO H, et al. Analysis of the full-length genome of a hepatitis E virus isolate obtained from a wild boar in Japan that is classifiable into a novel genotype[J]. J Gen Virol, 2011, 92(Pt 4): 902-908. DOI: 10.1099/vir.0.029470-0.
[5]	TAKAHASHI M, NISHIZAWA T, NAGASHIMA S, et al. Molecular characterization of a novel hepatitis E virus (HEV) strain obtained from a wild boar in Japan that is highly divergent from the previously recognized HEV strains[J]. Virus Res, 2014, 180: 59-69. DOI: 10.1016/j.virusres.2013.12.014.
[6]	WOO PC, LAU SK, TENG JL, et al. New hepatitis E virus genotype in bactrian camels, Xinjiang, China, 2013[J]. Emerg Infect Dis, 2016, 22(12): 2219-2221. DOI: 10.3201/eid2212.160979.
[7]	WOO PC, LAU SK, TENG JL, et al. New hepatitis E virus genotype in camels, the Middle East[J]. Emerg Infect Dis, 2014, 20(6): 1044-1048. DOI: 10.3201/eid2006.140140.
[8]	LEE GH, TAN BH, TEO EC, et al. Chronic infection with camelid hepatitis E virus in a liver transplant recipient who regularly consumes camel meat and milk[J]. Gastroenterology, 2016, 150(2): 355-357. e3. DOI: 10.1053/j.gastro.2015.10.048.
[9]	NIMGAONKAR I, DING Q, SCHWARTZ RE, et al. Hepatitis E virus: advances and challenges[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 96-110. DOI: 10.1038/nrgastro.2017.150.
[10]	ASRANI SK, DEVARBHAVI H, EATON J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70(1): 151-171. DOI: 10.1016/j.jhep.2018.09.014.
[11]	MA JX, LIU YY, LI Q, et al. Study on the safety and immunogenicity of simultaneous vaccination on both hepatitis E and hepatitis B vaccines[J]. Chin J Epidemiol, 2019, 40(4): 451-456. DOI: 10.3760/cma.j.issn.0254-6450.2019.04.015. 马建新, 刘瑶瑶, 李倩, 等. 戊型肝炎疫苗和乙型肝炎疫苗联合接种的安全性及免疫原性研究[J]. 中华流行病学杂志, 2019, 40(4): 451-456. DOI: 10.3760/cma.j.issn.0254-6450.2019.04.015.
[12]	National Health Commission of the People's Republic of China. The epidemic situation of statutory reporting infectious diseases in 2020[EB/OL]. (2021-03-12)[2022-09-01]. http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.shtml. 国家卫生健康委员会. 2020年全国法定传染病疫情概况[EB/OL]. (2021-03-12)[2022-09-01]. http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.shtml.
[13]	WANG W, CHEN KY, WU LM, et al. Genetic characteristics of hepatitis E in Shanghai, 2017—2020[J]. Dis Surveill, 2022, 37(1): 1-6. DOI: 10.3784/jbjc.202106210349. 王葳, 陈恺韵, 吴立梦, 等. 2017—2020年上海市人和猪戊型肝炎病毒基因型特征研究[J]. 疾病监测, 2022, 37(1): 1-6. DOI: 10.3784/jbjc.202106210349.
[14]	WU J, XU Y, CUI Y, et al. Dynamic changes of serum metabolites associated with infection and severity of patients with acute hepatitis E infection[J]. J Med Virol, 2022, 94(6): 2714-2726. DOI: 10.1002/jmv.27669.
[15]	WU J, BORTOLANZA M, ZHAI G, et al. Gut microbiota dysbiosis associated with plasma levels of Interferon-γ and viral load in patients with acute hepatitis E infection[J]. J Med Virol, 2022, 94(2): 692-702. DOI: 10.1002/jmv.27356.
[16]	European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection[J]. J Hepatol, 2018, 68(6): 1256-1271. DOI: 10.1016/j.jhep.2018.03.005.
[17]	LIU Y, MEI X, ZHANG YY, et al. Clinical features and risk factors of acute hepatitis E[J]. Chin Hepatol, 2022, 27(2): 218. DOI: 10.14000/j.cnki.issn.1008-1704.2022.02.022. 刘玉, 梅雪, 张宇一, 等. 急性戊型肝炎临床特征及危险因素分析[J]. 肝脏, 2022, 27(2): 218. DOI: 10.14000/j.cnki.issn.1008-1704.2022.02.022.
[18]	WU J, CHENG J, SONG S, et al. Value of red cell distribution width and red cell distribution width to platelet ratio in diagnosis and prognosis of HEV-related liver failure[J]. Chin J Clin Infect Dis, 2020, 13(6): 434-438. DOI: 10.3760/cma.j.issn.1674-2397.2020.06.007. 吴健, 成娟, 宋曙, 等. 红细胞分布宽度及红细胞分布宽度与血小板比值在HEV相关肝衰竭患者诊断及预后中的价值评估[J]. 中华临床感染病杂志, 2020, 13(6): 434-438. DOI: 10.3760/cma.j.issn.1674-2397.2020.06.007.
[19]	WANG Y, LIU H, LIU S, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study[J]. Liver Int, 2019, 39(12): 2291-2300. DOI: 10.1111/liv.14221.
[20]	PHAN T, DESMOND C. Hepatitis E infection with acute liver failure[J]. ACG Case Rep J, 2020, 7(3): e00361. DOI: 10.14309/crj.0000000000000361.
[21]	WANG Y, METSELAAR HJ, PEPPELENBOSCH MP, et al. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants[J]. Curr Opin Infect Dis, 2014, 27(4): 303-308. DOI: 10.1097/QCO.0000000000000074.
[22]	KAMAR N, ROSTAING L, IZOPET J. Hepatitis E virus infection in immunosuppressed patients: natural history and therapy[J]. Semin Liver Dis, 2013, 33(1): 62-70. DOI: 10.1055/s-0033-1338115.
[23]	Ministry of Health, the People's Republic of China. Diagnostic criteria for viral hepatitis E (WS-2008)[S]. Beijing: 2008. 中华人民共和国卫生部. 戊型病毒性肝炎诊断标准(WS-2008)[S]. 北京: 2008.
[24]	WU J, XIANG Z, ZHU C, et al. Extrahepatic manifestations related to hepatitis E virus infection and their triggering mechanisms[J]. J Infect, 2021, 83(3): 298-305. DOI: 10.1016/j.jinf.2021.07.021.
[25]	PISCHKE S, HARTL J, PAS SD, et al. Hepatitis E virus: Infection beyond the liver?[J]. J Hepatol, 2017, 66(5): 1082-1095. DOI: 10.1016/j.jhep.2016.11.016.
[26]	WANG Y, WANG S, WU J, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China[J]. EBioMedicine, 2018, 36: 122-130. DOI: 10.1016/j.ebiom.2018.08.053.
[27]	KAMAR N, BENDALL RP, PERON JM, et al. Hepatitis E virus and neurologic disorders[J]. Emerg Infect Dis, 2011, 17(2): 173-179. DOI: 10.3201/eid1702.100856.
[28]	WALLACE SJ, SWANN R, DONNELLY M, et al. Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective study[J]. Aliment Pharmacol Ther, 2020, 51(10): 974-986. DOI: 10.1111/apt.15704.
[29]	EL-MOKHTAR MA, SEDDIK MI, OSMAN A, et al. Hepatitis E virus mediates renal injury via the interaction between the immune cells and renal epithelium[J]. Vaccines (Basel), 2020, 8(3): 454. DOI: 10.3390/vaccines8030454.
[30]	HAFFAR S, BAZERBACHI F, LAKE JR. HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E[J]. Lancet Infect Dis, 2015, 15(3): 268. DOI: 10.1016/S1473-3099(15)70034-4.
[31]	PISCHKE S, POLYWKA S, HAAG F, et al. Association of hepatitis E virus and essential cryoglobulinemia?[J]. J Clin Virol, 2015, 67: 23-24. DOI: 10.1016/j.jcv.2015.03.020.
[32]	ABDELMAWLA D, MOEMEN D, DARWISH A, et al. Hepatitis E virus prevalence in Egyptian children with transfusion-dependent thalassemia[J]. Braz J Infect Dis, 2019, 23(1): 40-44. DOI: 10.1016/j.bjid.2019.01.007.
[33]	WU J, ZHANG X, LIU H, et al. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection[J]. Clin Biochem, 2019, 63: 24-31. DOI: 10.1016/j.clinbiochem.2018.11.012.
[34]	RAJ M, KUMAR K, GHOSHAL UC, et al. Acute hepatitis E-associated acute pancreatitis: A single center experience and literature review[J]. Pancreas, 2015, 44(8): 1320-1322. DOI: 10.1097/MPA.0000000000000402.
[35]	HAFFAR S, BAZERBACHI F, GARG S, et al. Frequency and prognosis of acute pancreatitis associated with acute hepatitis E: A systematic review[J]. Pancreatology, 2015, 15(4): 321-326. DOI: 10.1016/j.pan.2015.05.460.
[36]	HUANG F, LONG F, YU W, et al. High prevalence of hepatitis E virus in semen of infertile male and causes testis damage[J]. Gut, 2018, 67(6): 1199-1201. DOI: 10.1136/gutjnl-2017-314884.
[37]	HORVATITS T, WIβMANN JE, JOHNE R, et al. Hepatitis E virus persists in the ejaculate of chronically infected men[J]. J Hepatol, 2021, 75(1): 55-63. DOI: 10.1016/j.jhep.2020.12.030.
[38]	WU J, GUO N, ZHU L, et al. Seroprevalence of AIH-related autoantibodies in patients with acute hepatitis E viral infection: a prospective case-control study in China[J]. Emerg Microbes Infect, 2020, 9(1): 332-340. DOI: 10.1080/22221751.2020.1722759.
[39]	SERRATRICE J, DISDIER P, COLSON P, et al. Acute polyarthritis revealing hepatitis E[J]. Clin Rheumatol, 2007, 26(11): 1973-1975. DOI: 10.1007/s10067-007-0595-0.
[40]	WANG Y, CHEN G, PAN Q, et al. Chronic hepatitis E in a renal transplant recipient: the first report of genotype 4 hepatitis E virus caused chronic infection in organ recipient[J]. Gastroenterology, 2018, 154(4): 1199-1201. DOI: 10.1053/j.gastro.2017.12.028.
[41]	MA Z, de MAN RA, KAMAR N, et al. Chronic hepatitis E: Advancing research and patient care[J]. J Hepatol, 2022, 77(4): 1109-1123. DOI: 10.1016/j.jhep.2022.05.006.
[42]	VELAVAN TP, PALLERLA SR, JOHNE R, et al. Hepatitis E: An update on One Health and clinical medicine[J]. Liver Int, 2021, 41(7): 1462-1473. DOI: 10.1111/liv.14912.
[43]	ASLAN AT, BALABAN HY. Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment[J]. World J Gastroenterol, 2020, 26(37): 5543-5560. DOI: 10.3748/wjg.v26.i37.5543.
[44]	PÉRON JM, DALTON H, IZOPET J, et al. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin?[J]. J Hepatol, 2011, 54(6): 1323-1324; author reply 1324-1325. DOI: 10.1016/j.jhep.2011.01.009.
[45]	MANKA P, BECHMANN LP, COOMBES JD, et al. Hepatitis E virus infection as a possible cause of acute liver failure in Europe[J]. Clin Gastroenterol Hepatol, 2015, 13(10): 1836-1842. e2; quiz e157-158. DOI: 10.1016/j.cgh.2015.04.014.
[46]	LI LJ, WANG YM. Indications, standards and technical guidelines for artificial liver support system[J]. Chin J Clin Infect Dis, 2002, 20(4): 254-258. DOI: 10.3760/j.issn:1000-6680.2002.04.027. 李兰娟, 王宇明. 人工肝支持系统治疗指征, 标准及技术指南[J]. 中华传染病学杂志, 2002, 20(4): 254-258. DOI: 10.3760/j.issn:1000-6680.2002.04.027.
[47]	WU J, HUANG F, LING Z, et al. Altered faecal microbiota on the expression of Th cells responses in the exacerbation of patients with hepatitis E infection[J]. J Viral Hepat, 2020, 27(11): 1243-1252. DOI: 10.1111/jvh.13344.
[48]	KAMAR N, ROSTAING L, ABRAVANEL F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation[J]. Clin Infect Dis, 2010, 50(5): e30-e33. DOI: 10.1086/650488.
[49]	HAAGSMA EB, RIEZEBOS-BRILMAN A, van den BERG AP, et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b[J]. Liver Transpl, 2010, 16(4): 474-477. DOI: 10.1002/lt.22014.
[50]	MALLET V, NICAND E, SULTANIK P, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E[J]. Ann Intern Med, 2010, 153(2): 85-89. DOI: 10.7326/0003-4819-153-2-201007200-00257.
[51]	KAMAR N, ROSTAING L, ABRAVANEL F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection[J]. Gastroenterology, 2010, 139(5): 1612-1618. DOI: 10.1053/j.gastro.2010.08.002.
[52]	PISCHKE S, HARDTKE S, BODE U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience[J]. Liver Int, 2013, 33(5): 722-726. DOI: 10.1111/liv.12114.
[53]	KAMAR N, IZOPET J, TRIPON S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients[J]. N Engl J Med, 2014, 370(12): 1111-1120. DOI: 10.1056/NEJMoa1215246.
[54]	KAMAR N, CHATELUT E, MANOLIS E, et al. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function[J]. Am J Kidney Dis, 2004, 43(1): 140-146. DOI: 10.1053/j.ajkd.2003.09.019.
[55]	ALRIC L, BONNET D, LAURENT G, et al. Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-alpha therapy[J]. Ann Intern Med, 2010, 153(2): 135-136. DOI: 10.7326/0003-4819-153-2-201007200-00256.
[56]	ALRIC L, BONNET D, BEYNES-RAUZY O, et al. Definitive clearance of a chronic hepatitis E virus infection with ribavirin treatment[J]. Am J Gastroenterol, 2011, 106(8): 1562-1563. DOI: 10.1038/ajg.2011.158.
[57]	TAVITIAN S, PERON JM, HUGUET F, et al. Ribavirin for chronic hepatitis prevention among patients with hematologic malignancies[J]. Emerg Infect Dis, 2015, 21(8): 1466-1469. DOI: 10.3201/eid2108.150199.
[58]	DALTON HR, KEANE FE, BENDALL R, et al. Treatment of chronic hepatitis E in a patient with HIV infection[J]. Ann Intern Med, 2011, 155(7): 479-480. DOI: 10.7326/0003-4819-155-7-201110040-00017.
[59]	NEUKAM K, BARREIRO P, MACíAS J, et al. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin[J]. Clin Infect Dis, 2013, 57(3): 465-468. DOI: 10.1093/cid/cit224.
[60]	HAJJI H, GÉROLAMI R, SOLAS C, et al. Chronic hepatitis E resolution in a human immunodeficiency virus (HIV)-infected patient treated with ribavirin[J]. Int J Antimicrob Agents, 2013, 41(6): 595-597. DOI: 10.1016/j.ijantimicag.2013.02.005.